BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31841994)

  • 1. Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44.
    Wang H; Lu B; Ren S; Wu F; Wang X; Yan C; Wang Z
    Mol Ther Nucleic Acids; 2020 Mar; 19():218-227. PubMed ID: 31841994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
    Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
    Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
    Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
    Wan Y; Yuan Y; Pan Y; Zhang Y
    Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
    Chen ZY; Liu HY; Jiang N; Yuan JM
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
    Ma G; Zhu J; Liu F; Yang Y
    DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
    Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.
    Zhao H; Huang Y; Shi J; Dai Y; Wu L; Zhou H
    Front Pharmacol; 2018; 9():1312. PubMed ID: 30515095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
    Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
    Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
    Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.
    Yamauchi M; Yoshino I; Yamaguchi R; Shimamura T; Nagasaki M; Imoto S; Niida A; Koizumi F; Kohno T; Yokota J; Miyano S; Gotoh N
    Am J Cancer Res; 2011; 1(7):823-33. PubMed ID: 22016830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
    Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
    Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
    La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
    J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer.
    He W; Qin M; Cai Y; Gao X; Cao S; Wang Z; Chen H; Xu R
    Am J Cancer Res; 2021; 11(9):4329-4346. PubMed ID: 34659890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.